Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck & Co.’s Keytruda Gets Fighting Chance In TNBC

Successful KEYNOTE-522 Results May Sway FDA

May 13 2021

• By Alaric DeArment

Cancer — Merck & Co. announced positive results for Keytruda in TNBC • Source: Shutterstock

Related Content

Genentech’s Tecentriq Should Keep Its Accelerated Approval In Breast Cancer For Now, ODAC Says

Apr 29 2021

Trial Design Issues, Failure To Follow Guidance Likely to Hurt Merck At Keytruda Advisory Panel

Feb 08 2021

Modeling Is Not a Drug Approval Pathway: Why Merck Flunked Keytruda’s TNBC Advisory Panel

Feb 10 2021

Keytruda Poised To Add Early TNBC To Its Resumé As KEYNOTE-522 Hits First Endpoint

Sep 30 2019

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

Sep 14 2020

AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

May 10 2021

Keytruda Closing In On First-Line Metastatic Triple-Negative Breast Cancer

Feb 13 2020

Related Companies

Merck & Co., Inc.

Roche Holding AG

Genentech, Inc.

Gilead Sciences, Inc.

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Additional Topics

ImmunoOncology Biologics Research & Development Cancer

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window